Skip to content Skip to footer
Subscribe Now
INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2025 

Shots: Q3’25 was marked by major pharma and biotech M&A, led by BD’s $17.5B Reverse Morris Trust deal merging its Biosciences & Diagnostic Solutions unit with Waters, and Merck’s ~$10B acquisition of Verona Pharma The quarter spotlighted collaborations, notably GSK’s ~$12.5B agreement with Hengrui Pharma to co-develop up to 12 novel therapies across multiple disease areas. PharmaShots brings…
October 1, 2025

Read more

NEWS

Solid Biosciences & Kinea Bio Partner to Advance KNA-155 Using AAV-SLB101 for Dysferlin-Related Limb-Girdle Muscular Dystrophy

Shots:Solid Biosciences has entered into a non-exclusive global license & collaboration agreement with Kinea Bio to develop & commercialize KNA-155 for treating dysferlin-related limb-girdle muscular dystrophy, using Solid’s AAV-SLB101 capsidAs per the deal, Kinea Bio will receive a non-exclusive global license to utilize AAV-SLB101 for the delivery of KNA-155, which will enter IND-enabling studies…
September 24, 2025

Read more

NEWS

Avant Technologies and Austrianova Form Joint Venture Klothonova to Develop Klotho-Based Cell Therapies

Shots:Avant Technologies and Austrianova signed a joint venture and licensing agreement to form Klothonova, a 50/50 Nevada-based Joint Venture focused on developing cell-based therapies using encapsulated Klotho-producing cellsUnder the terms of the agreement, Klothonova will leverage Austrianova’s proprietary cell-encapsulation technology to develop and commercialize therapies for Alzheimer’s disease, heart disease, cancer, kidney disease,…
September 19, 2025

Read more

NEWS

BI Collaborates with Re-Vana Therapeutics to Develop Long-Acting Therapeutics for Eye Diseases

Shots:BI & Re-Vana Therapeutics have entered into a strategic collaboration & license agreement to develop extended-release therapies for eye diseasesAs per the deal, BI will obtain target exclusivity, while Re-Vana will receive over $1B in total potential deal value for the initial 3 targets, incl. upfront, development, regulatory, & commercial milestones, plus royalties…
July 29, 2025

Read more

NEWS

Chugai Pharmaceutical Partners with Gero to Develop Age-Related Disease Therapies

Shots:Chugai Pharmaceutical has entered into a joint research & license agreement with Gero to develop novel therapies for age-related diseasesChugai will develop novel antibody drugs using its proprietary antibody engineering techs for novel targets discovered by Gero's AI target discovery platform, & obtain exclusive global rights to research, develop, manufacture, & commercialize antibodies…
July 8, 2025

Read more

NEWS

Neurizon Therapeutics Licenses Monepantel from Elanco Animal Health to Accelerate NUZ-001 Commercialization

Shots:Elanco has granted Neurizon exclusive global rights to monepantel’s data package & related IP to develop & commercialize NUZ-001 & related compounds for the treatment, prevention, or palliation of ALS & other neurodegenerative diseases in humansAs per the deal, Elanco will receive an upfront payment, development milestone payments of $9.75M for the initial…
July 3, 2025

Read more

Q1 2025
INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2025 

Shots:   Q2’2025 highlights major acquisitions in the pharma and biotech industry along with collaboartion. The talk of the town remained Blueprint Medicines’ acquisition by Sanofi for ~$9.5B   The quarter highlighted Collaboartion, including Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid   PharmaShots brings the Quarterly digest compiling insights from…
July 1, 2025

Read more

Load more